drugset / Trial / NCT07357220

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

NCT07357220

Phase 1/2 Not yet recruiting 72 enrolled Akeso Shanghai Virogin Biotech Co., Ltd. · collab
RandomizedSequentialOpen-labelTreatment

Summary

An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.

Timeline

Start
2026-03-02
Primary completion
2027-02-28
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous
Subject VG2025 Unknown Other